Business Wire Science

Westlands Water District Statement

FRESNO, Calif.--(BUSINESS WIRE)--Upon this morning's release of the National Academy of Science's scientific assessment of the biological opinions concerning operations of the Central Valley Project and the State Water Project, Westlands Water District general manager Thomas Birmingham issues the following statement: Everyone involved in the debate over California's water crisis will be looking for aspects of this report that support their side. But the members of the panel are not ump

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 19:17:00 UT

ELCA Releases Draft Social Statement on Genetics

CHICAGO--(BUSINESS WIRE)--The Evangelical Lutheran Church in America (ELCA) released March 18 a 49-page draft social statement on genetics, a framework for discussion on a variety of current topics in the field including certain advances in medicine, reproductive cloning, human embryonic stem cells, and animal and plant genetic engineering. The full text of the Draft Social Statement on Genetics, an executive summary and a question-and-answer document are at http://www.elca.org/geneticsdraft on

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 18:03:00 UT

AdvanSource Biomaterials to Attend MEDTEC Europe 2010 Exhibition

WILMINGTON, Mass.--(BUSINESS WIRE)--AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced it will be exhibiting at the MEDTEC Europe 2010 Exhibition and Conference being held at the Landesmesse Stuttgart Messepiazza in Stuttgart, Germany, from March 23-25, 2010. The Company will continue promoting its expanding line of innovative biomaterials focused on the product development needs of the me

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 17:52:00 UT

Mayo Research: Intervention Drops Hospital Infection Rate by One-Third

ROCHESTER, Minn.--(BUSINESS WIRE)--Clostridium difficile (C. difficile) is the one of the leading pathogens causing hospital-acquired infection in the United States.

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 17:00:00 UT

New Deep Water Ocean Simulator Available at SwRI

SAN ANTONIO--(BUSINESS WIRE)--A new hyperbaric test chamber for items that require high-pressure, high-temperature (HPHT) testing is now available for use at Southwest Research Institute (SwRI). The deepwater ocean simulator is capable of attaining pressures of 30,000 psig at a rated temperature of 500 degrees F. The cylindrical simulator was designed, fabricated and built by SwRI in accordance with Section VIII-Division 2 rules of the ASME Boiler and Pressure Vessel Code. The Institute has prev

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 14:02:00 UT

BioImagene Partners with LigoLab to Develop Workflow Solution for Digital Pathology and Laboratory Information Systems

SUNNYVALE, Calif.--(BUSINESS WIRE)--BioImagene and LigoLab today announced the development of an interface between BioImagene’s digital pathology workflow and LigoLab’s anatomic pathology module of laboratory information system (LIS).

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 14:01:00 UT

A.P. Pharma Receives FDA Complete Response Letter for APF530

REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron utilizing the Company’s proprietary Biochronomer™ drug deli

Add to digg Add to del.icio.us Add to Newsvine Add to Reddit Add to Google Add to Yahoo My Web Email this Article

Fri, 19 Mar 2010 11:00:00 UT